Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate — cinnamon and chromium carry repeated meta-analytic support; two other ingredients carry almost none
What Gluco6 Claims To Be
Gluco6 is a capsule marketed for healthy blood sugar, positioned around GLUT-4 — the glucose transporter that moves sugar out of the bloodstream and into muscle and fat cells. The marketing angle is that supporting this transporter is a more upstream approach than simply blunting sugar absorption.
The mechanism is legitimate biology. GLUT-4 translocation genuinely is the rate-limiting step in insulin-stimulated glucose uptake. Whether a botanical capsule moves that needle in a person is a different question, and one the trials below answer only partly.
What’s Actually In It
Six named ingredients:
- Sukre (a branded sugar alternative)
- Cinnamon
- Gymnema sylvestre
- Green tea extract
- TeaCrine (theacrine)
- Chromium
No milligram amounts are published for any of them. That is the single biggest limitation in evaluating this product, because the cinnamon literature in particular shows dose-dependent effects — some benefits appear only below a certain intake.
What The Research Shows
According to PubMed, the ingredient evidence splits cleanly into two tiers.
Cinnamon has the deepest evidence base here. A 2025 systematic review and meta-analysis of 28 randomized controlled trials enrolling 3,054 people with type 2 diabetes found cinnamon supplementation significantly reduced fasting blood glucose (−15.26 mg/dL), postprandial glucose (−39.22 mg/dL), HbA1c (−0.56), and HOMA-IR (−0.76) versus control. Notably, the HbA1c, HOMA-IR, and BMI benefits appeared only at doses of 2 g/day or less — more was not better. DOI An independent dose-response meta-analysis of 24 RCTs reached the same directional conclusion on fasting glucose, HOMA-IR, and HbA1c, while finding no significant change in serum insulin. DOI
Worth flagging honestly: heterogeneity across those cinnamon trials was extremely high (I² values of 88–100% on several outcomes). That means the individual studies disagreed substantially with each other, and the pooled averages should be read as a rough signal rather than a precise number.
Cinnamon’s effect extends beyond diabetes. A separate meta-analysis of five RCTs in women with polycystic ovary syndrome found cinnamon significantly reduced HOMA-IR scores versus placebo. DOI
Gymnema has one clean, directly relevant trial. A monocentric, randomized, double-blind, placebo-controlled trial randomized 81 adults with mildly impaired fasting glucose (98–125 mg/dL) to a supplement containing Gymnema sylvestre extract plus zinc and chromium, or placebo, for three months. The lower-dose group showed significantly reduced fasting glucose and HbA1c versus placebo (p \< 0.001), with no evidence of kidney or liver toxicity. DOI Gymnema also appears as a component in a polyherbal prediabetes trial where the intervention group saw a 47% reduction in conversion to diabetes over six months alongside lifestyle modification. DOI
Chromium’s evidence is positive but softer than the marketing suggests. A meta-analysis of 119 randomized trials assessing nine different add-on nutrients in type 2 diabetes found chromium significantly improved HbA1c, fasting glucose, and HOMA-IR — one of only four nutrients out of nine to show a consistent glycemic effect. DOI An earlier meta-analysis of 13 trials found a significant fasting glucose reduction of −29.26 mg/dL, though with a wide confidence interval spanning −52.4 to −6.09. DOI
Two ingredients have essentially nothing behind them for this claim. Searching PubMed for glycemic trials of Sukre or TeaCrine (theacrine) returns no randomized human evidence for blood sugar outcomes. Theacrine is studied as a caffeine-adjacent stimulant, not a glucose agent. Their presence in the formula is not supported by the same class of research as the other four.
The Honest Verdict
What holds up: Cinnamon and chromium both have repeated meta-analytic support for modest improvements in fasting glucose and HbA1c. Gymnema has at least one well-designed placebo-controlled trial in exactly the population this product targets — people with mildly elevated fasting glucose rather than diagnosed disease. That is a better evidence base than most blood sugar supplements can claim.
What doesn’t: The effect sizes are modest, not transformative. A 0.5-point HbA1c reduction is real and clinically meaningful at the margin, but it is not a substitute for medication in anyone who needs medication. The trial heterogeneity is uncomfortably high. Doses are undisclosed, so there is no way to know whether the cinnamon in this capsule falls in the ≤2 g/day window where the benefits clustered. And a sixth of the formula — TeaCrine — has no glycemic evidence at all.
Who this makes sense for: Someone with mildly elevated fasting glucose who is already working on diet and activity and wants an evidence-plausible addition. Every trial above framed these ingredients as adjuncts layered on top of lifestyle or medication, never as replacements.
Who should skip it: Anyone with diagnosed diabetes who is thinking of substituting this for prescribed therapy. Also anyone already on glucose-lowering medication who has not cleared it with their doctor — cinnamon, gymnema, and chromium all push in the same direction as those drugs, and stacking them without supervision is how people end up hypoglycemic.
Check current pricing and availability
View Gluco6 on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your physician before starting any supplement, especially if you have a diagnosed condition or take medication.
Research cited via PubMed:
- de Moura SL, et al. Nutr Rev. 2025;83(2):249-279. DOI
- Moridpour AH, et al. Phytother Res. 2024;38(1):117-130. DOI
- Heshmati J, et al. J Food Biochem. 2021;45(1):e13543. DOI
- Buccato DG, et al. Nutrients. 2024;16(15):2459. DOI
- Nakanekar A, et al. J Ayurveda Integr Med. 2019;10(4):284-289. DOI
- Kim Y, et al. Arch Pharm Res. 2022;45(3):185-204. DOI
- San Mauro-Martin I, et al. Nutr Hosp. 2016;33(1):27. DOI